TriMix MEL

Drug Profile

TriMix MEL

Alternative Names: ECI-003; ECI-006; in vivo TriMix mRNA

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator eTheRNA Immunotherapies
  • Developer eTheRNA Immunotherapies; Vrije Universiteit Brussel
  • Class Antineoplastics; Immunotherapies; RNA
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Malignant melanoma
  • Phase I Hepatocellular carcinoma; HIV infections
  • Preclinical Hepatitis B; Human papillomavirus infections

Most Recent Events

  • 12 Jul 2017 Phase-I clinical trials in Hepatocellular carcinoma in Belgium (Injection) (eTheRNA pipeline, July 2017)
  • 12 Jul 2017 Phase-I clinical trials in HIV infections in Belgium (Injection) (eTheRNA pipeline, July 2017)
  • 12 Jul 2017 Phase-I/II clinical trials in Breast cancer in Belgium (Intratumoural) (eTheRNA pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top